Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis

References

• World Health OrganizationThe top 10 causes of death [updated January 2017] Available from: http://www.who.int/gho/mortality_burden_disease/causes_death/top_10/en/Accessed 17 September, 2018
   Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management and prevention of COPD2018 Available from: http://goldcopd.orgAccessed 17 September, 2018
   Google Scholar
• RohatgiAWebPlotDigitizer Version 4.1 [updated 8 January 2018] Available from: https://automeris.io/WebPlotDigitizer/. Accessed 17 September, 2018
   Google Scholar
• HigginsJPAltmanDGGotzschePCJuniPMoherDOxmanADThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• WhiteIRMultivariate random-effects meta-regression: updates to mvmetaStata J201111255270
   Web of Science ®Google Scholar
• HarrisRJBradburnMJDeeksJJHarbordRMAltmanDGSterneJAMetan: fixed and random-effects meta-analysisStata J200881328
   Web of Science ®Google Scholar
• CazzolaMMacNeeWFau MartinezFJOutcomes for COPD pharmacological trials: from lung function to biomarkers2008312416469
   Google Scholar
• DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
   PubMedGoogle Scholar
• MahlerDAWitekTJThe MCID of the transition dyspnea index is a total score of one unitCOPD2005219910317136969
   PubMedGoogle Scholar
• AlmaHde JongCJelusicDHealth status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important differenceNPJ Prim Care Respir Med2016261604127597571
   PubMed Web of Science ®Google Scholar
• ChaimaniAHigginsJPMavridisDSpyridonosPSalantiGGraphical tools for network meta-analysis in STATAPLoS One2013810e7665424098547
   PubMed Web of Science ®Google Scholar
• WestwoodMBourbeauJJonesPWCerulliACapkun-NiggliGWorthyGRelationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic reviewRespir Res2011124021477298
   PubMed Web of Science ®Google Scholar
• KerwinEMD’UrzoADGelbAFLakkisHGarciaGil ECaractaCFACCORD I study investigatorsEfficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)COPD2012929010122320148
   PubMedGoogle Scholar
• RennardSIScanlonPDFergusonGTACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patientsClin Drug Investig20133312893904
   PubMed Web of Science ®Google Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J201240483083622441743
   PubMed Web of Science ®Google Scholar
• LeeSHLeeJYooKHEfficacy and safety of aclidinium bromide in patients with COPD: a Phase 3 randomized clinical trial in a Korean populationRespirology20152081222122826370136
   PubMed Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• WangCSunTHuangYEfficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 studyInt J Chron Obstruct Pulmon Dis201510576825609940
   PubMed Web of Science ®Google Scholar
• ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting musca-rinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med2014144424438744
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• AmbrosinoNFoglioKBalzanoGPaggiaroPLLessiPKestenSTiotropium and exercise training in COPD patients: effects on dyspnea and exercise toleranceInt J Chron Obstruct Pulmon Dis20083477178019281092
   PubMedGoogle Scholar
• BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax200358539940412728159
   PubMed Web of Science ®Google Scholar
• CasaburiRBriggsDDDonohueJFSerbyCWMenjogeSSWitekTJThe spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study GroupChest200011851294130211083677
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• ChanCKMaltaisFSigouinCHaddonJMFord GTSAFE Study GroupA randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary diseaseCan Respir J200714846547218060091
   PubMed Web of Science ®Google Scholar
• CovelliHBhattacharyaSCassinoCConoscentiCKestenSAbsence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary diseasePharmacotherapy200525121708171816305289
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLotvallJOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• JohanssonGLindbergARombergKNordströmLGerkenFRoquetABronchodilator efficacy of tiotropium in patients with mild to moderate COPDPrim Care Respir J200817316917518536860
   PubMedGoogle Scholar
• MoitaJBárbaraCCardosoJTiotropium improves FEV1 in patients with COPD irrespective of smoking statusPulm Pharmacol Ther200821114615117693107
   PubMed Web of Science ®Google Scholar
• NiewoehnerDERiceKCoteCPrevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med2005143531732616144890
   PubMed Web of Science ®Google Scholar
• FreemanDLeeAPriceDEfficacy and safety of tiotropium in COPD patients in primary care – the SPiRiva Usual CarE (SPRUCE) studyRespir Res200784517605774
   PubMed Web of Science ®Google Scholar
• TroostersTSciurbaFCDecramerMTiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trialNPJ Prim Care Respir Med2014241400324841833
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSBurkhartDKestenSMenjogeSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• CelliBDecramerMKestenSLiuDMehraSTashkinDPMortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20091801094895519729663
   PubMed Web of Science ®Google Scholar
• VerkindreCBartFAguilaniuBThe effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary diseaseRespiration200673442042716484769
   PubMed Web of Science ®Google Scholar
• ZhouYZhongNSLiXTiotropium in early-stage chronic obstructive pulmonary diseaseN Engl J Med20173771092393528877027
   PubMed Web of Science ®Google Scholar
• VinckenWvan NoordJAGreefhorstAPBantjeTAKestenSKorduckiLImproved health outcomes in patients with COPD during 1 yr’s treatment with tiotropiumEur Respir J200219220921611871363
   PubMed Web of Science ®Google Scholar
• van NoordJABantjeTAElandMEKorduckiLCornelissenPJA randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study GroupThorax200055428929410722768
   PubMed Web of Science ®Google Scholar
• BatemanESinghDSmithDEfficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studiesInt J Chron Obstruct Pulmon Dis2010519720820714373
   PubMedGoogle Scholar
• BatemanEDTashkinDSiafakasNA one-year trial of tiotropium Respimat plus usual therapy in COPD patientsRespir Med2010104101460147220620037
   PubMed Web of Science ®Google Scholar
• VoshaarTLapidusRMaleki-YazdiRA randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPDRespir Med20081021324117996436
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACalverleyPThe Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationaleRespir Res2013144023547660
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDDahlRDevinsTDisseBTiotropium Respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
   PubMed Web of Science ®Google Scholar
• AnzuetoAWiseRCalverleyPThe Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: spirometry outcomesRespir Res20151610726369563
   PubMed Web of Science ®Google Scholar
• TrivediRRichardNMehtaRChurchAUmeclidinium in patients with COPD: a randomised, placebo-controlled studyEur Respir J2014431728123949963
   PubMed Web of Science ®Google Scholar
• FeldmanGMaltaisFKhindriSA randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPDInt J Chron Obstruct Pulmon Dis20161171973027103795
   PubMed Web of Science ®Google Scholar
• RheaultTKhindriSVahdati-BolouriMChurchAFahyWAA randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPDERJ Open Res201622
   Google Scholar
• D’UrzoADRennardSIKerwinEMMergelVLeselbaumARCaractaCFAUGMENT COPD study investigatorsEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• VogelmeierCPaggiaroPLDorcaJEfficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a Phase 3 COPD studyEur Respir J20164841030103927492833
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med2013107101558156723867808
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRVestboJRocheNAyersRTIndacaterol–glycopyrronium versus salmeterol–fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• ZhongNWangCZhouXZhangNHumphriesMWangLLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• BuhlRMagderSBothnerULong-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary diseaseRespir Med2017122586627993292
   PubMed Web of Science ®Google Scholar
• KerwinEMKalbergCJGalkinDVUmeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week studyInt J Chron Obstruct Pulmon Dis20171274575528280319
   PubMed Web of Science ®Google Scholar
• SilerTMDonaldACO’DellDChurchAFahyWAA randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol62.5/25 μg on health-related quality of life in patients with COPDInt J Chron Obstruct Pulmon Dis20161197197927274218
   PubMed Web of Science ®Google Scholar
• ZhengJZhongNNewlandsAChurchAGohAHEfficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled studyInt J Chron Obstruct Pulmon Dis2015101753176726366068
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
   PubMed Web of Science ®Google Scholar
• DonohueJFWorsleySZhuCQHardakerLChurchAImprovements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med2015109787088126006754
   PubMed Web of Science ®Google Scholar
• SinghDWorsleySZhuCQHardakerLChurchAUmeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trialBMC Pulm Med2015159126286141
   PubMed Web of Science ®Google Scholar
• TashkinDPRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200018778120
   PubMed Web of Science ®Google Scholar
• RennardSITashkinDPMcelhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
   PubMed Web of Science ®Google Scholar
• BhattSPDransfieldMTCockcroftJRA randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPDInt J Chron Obstruct Pulmon Dis20171235136528176907
   PubMed Web of Science ®Google Scholar
• KerwinEMScott-WilsonCSanfordLA randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPDRespir Med2013107456056923352226
   PubMed Web of Science ®Google Scholar
• MartinezFJBosciaJFeldmanGFluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trialRespir Med2013107455055923332861
   PubMed Web of Science ®Google Scholar
• CovelliHPekBSchenkenbergerIScott-WilsonCEmmettACrimCEfficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular riskInt J Chron Obstruct Pulmon Dis201611112
   PubMed Web of Science ®Google Scholar
• PepinJLCockcroftJRMidwinterDSharmaSRubinDBAndreasSLong-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropiumChest201414661521153025058845
   PubMed Web of Science ®Google Scholar
• DransfieldMTFeldmanGKorenblatPEfficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patientsRespir Med201410881171117924998880
   PubMed Web of Science ®Google Scholar
• AgustíAde TeresaLde BackerWA comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPDEur Respir J201443376377224114969
   PubMed Web of Science ®Google Scholar
• AsaiKKobayashiAMakiharaYJohnsonMAnti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20151080381125945045
   PubMed Web of Science ®Google Scholar
• HananiaNADarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPDChest2003124383484312970006
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200216681084109112379552
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• JonesPWAndersonJACalverleyPMHealth status in the TORCH study of COPD: treatment efficacy and other determinants of changeRespir Res2011127121627828
   PubMed Web of Science ®Google Scholar
• JenkinsCRJonesPWCalverleyPMEfficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyRespir Res2009105919566934
   PubMed Web of Science ®Google Scholar
• ZhengJPYangLWuYMThe efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPDChest200713261756176317951625
   PubMed Web of Science ®Google Scholar
• CazzolaMAndòFSantusPA pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPDPulm Pharmacol Ther200720555656116914336
   PubMed Web of Science ®Google Scholar
• PerngDWTaoCWSuKCTsaiCCLiuLYLeeYCAnti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPDEur Respir J200933477878419129278
   PubMed Web of Science ®Google Scholar
• DahlRGreefhorstLANowakDInhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001164577878411549532
   PubMed Web of Science ®Google Scholar
• TaylorJKotchARiceKIpratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPDChest200112041253126111591569
   PubMed Web of Science ®Google Scholar
• SionKYHuismanELPunekarYSNayaIIsmailaASA network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) combinations in COPDPulmonary Therapy201732297316
   PubMedGoogle Scholar
• CopeSDonohueJFJansenJPComparative efficacy of long-acting bronchodilators for COPD-a network meta-analysisRespiratory research201314110024093477
   PubMed Web of Science ®Google Scholar
• KarabisALindnerLMocarskiMHuismanEGreeningAComparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysisInt J Chron Obstruct Pulmon Dis2013840524043936
   PubMed Web of Science ®Google Scholar
• IsmailaASHuismanELPunekarYSKarabisAComparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysisInt J Chron Obstruct Pulmon Dis201510249526604738
   PubMed Web of Science ®Google Scholar
• SchlueterMGonzalez-RojasNBaldwinMGroenkeLVossFReasonTComparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysisTher Adv Respir Dis20161028910426746383
   PubMed Web of Science ®Google Scholar
• HuismanELCockleSMIsmailaASKarabisAPunekarYSComparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysisInt J Chron Obstruct Pulmon Dis2015101863
   Web of Science ®Google Scholar